Earlier this year, GW Pharmaceuticals (NASDAQ: GWPH) stock rallied on clinical success with its cannabis-derived epilepsy treatment. After falling more than 40% in the first months of 2016, the volatile marijuana stock is up about 16% year to date. 3 Reasons GW Pharmaceuticals’ Stock Could Rise

thumbnail courtesy of qctimes.com